REFERENCES
- Alexander D. L., Zhang L., Foroozesh M., Alworth W. L., Jefcoate C. R. Metabolism-based polycyclic aromatic acetylene inhibition of CYP1B1 in 10T1/2 cells potentiates aryl hydrocarbon receptor activity. Toxicol. Appl. Pharmacol. 1999; 161: 123–139, [PUBMED], [INFOTRIEVE], [CSA]
- Annas A., Granberg L., Brittebo E. B. Differential response of cultured human umbilical vein and artery endothelial cells to Ah receptor agonist treatment: CYP-dependent activation of food and environmental mutagens. Toxicol. Appl. Pharmacol. 2000; 169: 94–101, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bejjani B. A., Lewis R. A., Tomey K. F., Anderson K. L., Dueker D. K., Jabak M., Astle W. F., Otterud B., Leppert M., Lupksi J. R. Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. Am. J. Hum. Genet. 1998; 62: 325–333, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bendiit E. P., Benditt J. M. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc. Natl. Acad. Sci. U. S. A. 1973; 70: 1753–1756, [CSA]
- Bhattacharyya K. K., Brake P. B., Eltom S. E., Otto S. A., Jefcoate C. R. Identification of a rat adrenal cytochrome P450 active in polycyclic aromatic hydrocarbon metabolism as rat CYP1B1. Demonstration of a unique tissue-specific pattern of hormonal and aryl hydrocarbon receptor-linked regulation. J. Biol. Chem. 1995; 270: 11595–11602, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Binkova B., Strejc P., Boubelik O., Stavkova Z., Chvatlova I., Sram R. J. DNA adducts and human atherosclerotic lesions. Int. J. Hyg. Environ. Health. 2001; 204: 49–54, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Black V. H., Quattrochi L. C. Molecular cloning of the guinea pig CYP1A2 gene 5′-flanking region: identification of functional aromatic hydrocarbon response element and characterization of CYP1A2 expression in GPC16 cells. Drug Metab. Dispos. 2004; 32: 595–602, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bond J. A., Gown A. M., Yang H. L., Benditt R. P., Juchau M. R. Further investigations on the capacity of polynuclear aromatic hydrocarbons to elicit atherosclerotic lesions. J. Toxicol. Environ. Health. 1981; 7: 327–335, [PUBMED], [INFOTRIEVE], [CSA]
- Bowes R. C., Parrish A. R., Steinberg M. A., Willet K. L., Zhao W., Savas U., Jefcoate C. R., Safe S. H., Ramos K. S. Atypical cytochrome P450 induction profiles in glomerular mesangial cells at the mRNA and enzyme level. Evidence for CYP1A1 and CYP1B1 expression and their involvement in benzo[a]pyrene metabolism. Biochem. Pharmacol. 1996; 52: 587–595, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bral C. M., Ramos K. S. Identification of benzo[a]pyrene-inducible cis-acting elements within c-Ha-ras transcriptional regulatory sequences. Mol. Pharmacol. 1997; 52: 974–982, [PUBMED], [INFOTRIEVE], [CSA]
- Bridges B. A., Bowyer D. E., Hansen E. S., Penn A., Wakabayashi K. The possible involvement of somatic mutations in the development of atherosclerotic plaques. Mutat. Res. 1990; 239: 143–187, [CSA]
- Cavalieri E. L., Rogan E. G. Central role of radical cations in metabolic activation of polycylic aromatic hydrocarbons. Xenobiotica 1995; 25: 677–688, [PUBMED], [INFOTRIEVE], [CSA]
- Chang B. L., Zheng S. L., Isaacs S. D., Turner A., Hawkins G. A., Wiley K. E., Bleecker E. R., Walsh P. C., Meyers D. A., Isaacs W. B., Xu J. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br. J. Cancer. 2003; 89: 1524–1529, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Choudary D., Jansson I., Sarfarazi M., Schenkman J. B. Xenobiotic-metabolizing cytochromes P450 in ontogeny: evolution perspective. Drug Metab. Rev. 2004; 36: 549–568, [CROSSREF], [CSA]
- De Flora S., Izzotti A., Randerath K., Randerath E., Bartsch H., Nair J., Balansky R., Schooten F. V., Degan P., Fronza G., Walsh D., Lewtas J. DNA adducts and chronic degenerative diseases. Pathogenic relevance and implications in preventive medicine. Mutat. Res. 1996; 366: 197–238, [PUBMED], [INFOTRIEVE], [CSA]
- Denissenko M. F., Pao A., Tang M., Pfeifer G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot spots in P53. Science 1996; 274: 430–432, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Emberson J. R., Whincup P. H., Lawlor D. A., Montaner D., Ebrahim S. Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart 2005; 91: 451–455, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Galvan N., Moorthy B., MacWilliams P. S., Czuprynski C. J., Jefcoate C. R. Induction of CYP1A1 and CYP1B1 in liver and lung by benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene do not affect distribution of polycyclic hydrocarbons to target sites: Role of AhR and CYP1B1 in bone marrow cytotoxicity. Toxicol. Appl. Pharmacol. 2005; 202: 244–257, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gelboin H. V. Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol. Rev. 1980; 60: 1107–1166, [PUBMED], [INFOTRIEVE], [CSA]
- Giachelli C. M., Majesky M. W., Schwartz S. M. Developmentally regulated cytochrome P4501A1 expression in cultured rat vascular smooth muscle cells. J. Biol. Chem. 1991; 266: 3981–3986, [PUBMED], [INFOTRIEVE], [CSA]
- Granberg L., Ostergren A., Brandt I., Brittebo E. B. CYP1A1 and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(A)anthracene in endothelial cells. Drug Metab. Dispos. 2003; 31: 259–265, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Guengerich F. P. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 1988; 48: 2946–2954, [PUBMED], [INFOTRIEVE], [CSA]
- Hemminki K. Environmental carcinogens. Chemical Carcinogenesis and Mutagenesis I, C. S. Cooper, P. L. Grover. Springer-Verlag. 1990; 33–61
- Hemminki K. DNA adducts, mutation, and cancer. Carcinogenesis 1993; 14: 2007–2012, [PUBMED], [INFOTRIEVE], [CSA]
- Izzotti A., Flora S. D., Petrilli G. L., Gallagher J., Rojas M., Alexandrov K., Bartsch H., Lewtas J. Cancer biomarkers in human atherosclerotic lesions: detection of DNA adducts. Cancer Epidemiol. Biomark. Prev. 1995; 4: 105–110, [CSA]
- Joseph P., Jaiswal A. K. NAD(P)H:quinone reductasel (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc. natl. Acad. Sci. U. S. A. 1994; 91: 8413–8417, [PUBMED], [INFOTRIEVE], [CSA]
- Juchau A. R., Bond J. A., Benditt E. P. Aryl-monooxygenase and cytochrome P450 in the aorta: possible role in atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 1976; 73: 3723–3725, [PUBMED], [INFOTRIEVE], [CSA]
- Kangavari S., Matetzky S., Shah P. K., Yano J., Chyu K. Y., Fishbein M. C., Cercek B. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J. Cardiovas. Pharmacol. Ther. 2004; 9: 291–298, [CSA]
- Karim R., Buchana T. A., Hodis H. N., Li Y., Mack W. J. The association of smoking and subclinical atherosclerosis in type 2 diabetes: modification by duration of diabetes. Diabet. Med. 2005; 22: 81–87, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Karyala S., Guo J., Sartor M., Medvedovic M., Kann S., Puga A., Ryan P., Tomlinson C. R. Different global gene expression profiles in benzo[a]pyrene-and dioxin-treated vascular smooth muscle cells of AHR-knockout and wild type mice. Cardiovasc. Toxicol. 2004; 4: 47–73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kerzee J. K., Ramos K. S. Activation of c-Ha-ras by benzo[a]pyrene in vascular smooth muscle cells involves redox stress and aryl hydrocarbon receptor. Mol. Pharmacol. 2000; 58: 152–158, [PUBMED], [INFOTRIEVE], [CSA]
- Kerzee J. K., Ramos K. S. Constitutive and inducible expression of CYP1A1 and CYP1B1 in vascular smooth muscle cells: role of the AHR bHLH/PAS transcription factor. Circ Res 2001; 89: 573–582, [PUBMED], [INFOTRIEVE], [CSA]
- Li D., Wang M., Cheng L., Spitz M. R., Hittelman W. N., Wei Q. In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 1996; 56: 3638–3641, [PUBMED], [INFOTRIEVE], [CSA]
- Lu K. P., Ramos K. S. Identification of genes differentially expressed in vascular smooth muscle cells following benzo[a]pyrene challenge: implications for chemical atherogenesis. Biochem. Biophys. Res. Commun. 1998; 253: 828–833, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lu K. P., Hallberg L. M., Tomlinson J., Ramos K. S. Benzo[a]pyrene activates L1Md retrotransposon and inhibits DNA repair in vascular smooth muscle cells. Mutat. Res. 2000; 454: 35–44, [PUBMED], [INFOTRIEVE], [CSA]
- Majesky M. W., Yang H.-Y., Benditt E. P., Juchau M. R. Carcinogenesis and atherogenesis; differences in monooxygenase inducibility and bioactivation of benzo[a]pyrene in aortic and hepatic tissues of atherosclerosis-susceptible pigeons. Carcinogenesis 1983; 4: 647–652, [PUBMED], [INFOTRIEVE], [CSA]
- Miller K. P., Ramos K. S. Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons. Drug Metab. Rev. 2001; 33: 1–35, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Miller K. P., Chen Y. H., Hastings V. L., Bral C. M., Ramos K. S. Profiles of antioxidant/electrophile response element (ARE/EpRE) nuclear protein binding and c-Ha-ras transactivation in vascular smooth muscle cells treated with oxidative metabolites of benzo[a]pyrene. Biochem. Pharmacol. 2000; 60: 1285–1296, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moorthy B., Randerath K. Pentachlorophenol enhances 9-hydroxybenzo[a]pyrene-induced hepatic DNA adduct formation in vivo and inhibits microsomal epoxide hydrolase and glutathione S-transferase activities in vitro: likely inhibition of epoxide detoxication by pentachlorophenol. Arch. Toxicol. 1997; 70: 696–703, [CROSSREF], [CSA]
- Moorthy B., Chen S., Li D., Randerath K. 3-Methylcholanthrene-inducible liver cytochrome(s) P450 in female Sprague-Dawley rats: possible link between P450 turnover and formation of DNA adducts and I-compounds. Carcinogenesis 1993; 14: 879–886, [PUBMED], [INFOTRIEVE], [CSA]
- Moorthy B., Sriram P., Randerath K. Chemical structure-and time-dependent effects of polycyclic aromatic hydrocarbons-type inducers on rat liver cytochrome P450, DNA adducts, and I-compounds. Fundam. Appl. Toxicol. 1994; 22: 549–560, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moorthy B., Parker K. M., Smith C. V., Bend J. R., Welty S. E. Potentiation of oxygen-induced lung injury in rats by the mechanism-based cytochrome P-450 inhibitor, 1-aminobenzotriazole. J. Pharmacol. Exp. Ther. 2000; 292: 553–560, [PUBMED], [INFOTRIEVE], [CSA]
- Moorthy B., Miller K. P., Jiang W., Ramos K. S. The atherogen 3-methylcholanthrene induces multiple DNA adducts in mouse aortic smooth muscle cells: role of cytochrome P4501B1. Cardiovas. Res. 2002; 53: 1002–1009, [CROSSREF], [CSA]
- Moorthy B., Miller K. P., Jiang W., Williams E. S., Kondraganti S. R., Ramos K. S. Role of cytochrome P4501B1 in benzo[a]pyrene bio-activation to mouse vascular smooth muscle cells: evidence from 32P-postlabeling for formation of 3-hydroxybenzo[a]pyrene and benzo[a]pyrene-3,6-quinone as major proximate genotoxic intermediates. J Pharmacol. Exp. Ther. 2003; 395: 394–401, [CROSSREF], [CSA]
- Narvaez M. J., Anderson G. R., Pickwell G. V., Quattrochi L. C. Characterization of adjacent E-box and nuclear factor 1-like DNA binding sequence in the human CYP1A2 promoter. J. Biochem. Mol. Toxicol. 2005; 19: 78–86, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nebert D. W. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. CRC Crit. Rev. Toxicol. 1989; 20: 153–174, [CSA]
- Nelson D. R., Zeldin D. C., Hoffman S. M., Maltais L. J., Wain H. M., Nebert D. W. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004; 14: 1–18, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nissen S. E., Tuzeu E. M., Schoenhagen P., Crowe T., Sasiela W. J., Tsai J., Orazem J., Magorien R. D., O Shaughnessy C., Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary heart disease. N. Engl. J. Med. 2005; 352: 29–38, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Okey A. B., Riddick D. S., Harper P. A. The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol. Lett. 1994; 70: 1–22, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Otto S., Marcus C., Pidgeon C., Jefcoate C. A novel adrenocorticotropin-inducible cytochrome P450 from rat adrenal microsomes catalyses polycyclic aromatic hydrocarbon metabolism. Endocrinology 1991; 129: 970–982, [PUBMED], [INFOTRIEVE], [CSA]
- Ou X., Ramos K. S. Regulation of cytochrome P4501A1 gene expression in vascular smooth muscle cells through arylhydrocarbon receptor-mediated signal transduction requires a protein synthesis inhibitor. Arch. Biochem. Biophys. 1995; 316: 116–122, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Paigen B., Havens M. B., Morrow A. Effect of 3-methylcholanthrene on the development of aortic lesions in mice. Cancer Res 1985; 45: 3850–3855, [PUBMED], [INFOTRIEVE], [CSA]
- Paigen B., Holmes P., Morrow A., Mitchell D. Effects of 3-methylcholanthrene on atherosclerosis in two congenic strains of mice with different susceptibilities to methylcholanthrene-induced tumors. Cancer Res 1986; 46: 3321–3324, [PUBMED], [INFOTRIEVE], [CSA]
- Pelkonen O., Nebert D. W. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol. Rev. 1982; 34: 189–222, [PUBMED], [INFOTRIEVE], [CSA]
- Penn A., Snyder C. Arteriosclerosis plaque development is ‘promoted’ by polynuclear aromatic hydrocarbons. Carcinogenesis 1988; 9: 2185–2189, [PUBMED], [INFOTRIEVE], [CSA]
- Penn A., Garie S. J., Warren L. Transforming gene in human atherosclerotic plaque DNA. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 7951–7955, [PUBMED], [INFOTRIEVE], [CSA]
- Pottenger L. H., Jefcoate C. R. Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. Carcinogenesis 1990; 11: 321–327, [PUBMED], [INFOTRIEVE], [CSA]
- Quattrochi L. C., Vu T., Tukey R. H. The human CYP1A2 gene and induction by 3-methylcholantherene. A region of DNA that supports AH-receptor binding and promoter-specific induction. J. Biol. Chem. 1994; 269: 6949–6954, [PUBMED], [INFOTRIEVE], [CSA]
- Ramos K. Redox regulation of c_Ha-ras and osteopontin signaling in vascular smooth muscle cells: implications in chemical atherogenesis. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 243–265, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ramos K. S., Zhang Y., Sadhu D. N., Chapkin R. C. The induction of proliferative phenotypes in vascular smooth muscle cells by benzo(a)pyrene. Arch. Biochem. Biophys. 1996; 332: 213–222, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ryu D. Y., Hodgson E. Constitutive expression and induction of CYP1B1 mRNA in the mouse. J. Biochem. Mol. Toxicol. 1999a; 13: 249–251, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sadhu D. N., Merchant M., Safe S. H., Ramos K. S. Modulation of protooncogene expression in rat aortic smooth muscle cells by benzo(a)pyrene. Arch. Biochem. Biophys. 1993; 300: 124–131, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Salama S. A., Au W. W., Hunter G. C., Sheahan R. G., Badary O. A., Abdel-Naim A. B., Hamada F. M. Polymorphic metabolizing genes and susceptibility to atherosclerosis among cigarette smokers. Environ. Mol. Mutagen. 2002; 40: 153–160, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Savas U., Jefcoate C. R. Dual regulation of cytochrome P450EF expression via the aryl hydrocarbon receptor and protein stabilization in C#H/10T1/2 cells. Mol. Pharmacol. 1994; 45: 1153–1159, [PUBMED], [INFOTRIEVE], [CSA]
- Shimada T., Hayes C. L., Yamazaki H., Amin S., Hecht S. S., Guengerich F. P., Sutter T. R. Activation of chemically diverse procarcinogens by human cytochrome P4501B1. Cancer Res 1996; 56: 2979–2984, [PUBMED], [INFOTRIEVE], [CSA]
- Shimada T., Yamazaki H., Foroozesh M., Hopkins N. E., Alworth W. L., Guengerich F. P. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 1998; 11: 1048–1056, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shimada T., Oda Y., Gilam E. M., Guengerich F. P., Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P4501A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab. Dispos. 2001; 29: 1176–1182, [PUBMED], [INFOTRIEVE], [CSA]
- Stegeman J. J., Hahn M. E., Weisbrod R., Woodin B. R., Joy J. S., Najibi S., Cohen R. A. Induction of cytochrome P4501A1 by arylhydrocarbon receptor agonists in porcine aorta endothelial cells in culture and cytochrome P4501A1 activity in intact cells. Mol. Pharmacol. 1995; 47: 296–306, [PUBMED], [INFOTRIEVE], [CSA]
- Stoilov I., Akarsu A. N., Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 1997; 6: 641–647, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thirman M. J., Albrecht J. H., Krueger M. A., Erickson R. R., Cherwitz D. L., Park S. S., Gelboin H. V., Holtzman J. L. Induction of cytochrome CYP1A1 and formation of toxic metabolites of benzo[a]pyrene by rat aorta: a possible role in atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 5397–5401, [PUBMED], [INFOTRIEVE], [CSA]
- Tian Y., Ke S., Chen M., Sheng T. Interactions between the aryl hydrocarbon receptor and P-TEFb. Sequential recruitment of transcription factors and differential phosphorylation of C-terminal domain of RNA polymerase II at cyp1a1 promoter. J. Biol. Chem. 2003; 278: 44041–44048, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Uno S., Dalton T. P., Shertzer H. G., Genter M. B., Warshawsky D., Talaska G., Nebert D. W. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1 (−/−) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem. Biophys. Res. Commun. 2001; 289: 1049–1056, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang X. L., Mahaney M. C. Genotype-specific effects of smoking on risk of CHD. Lancet 2001; 358: 87–88, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zeiher A. M., Volker S., Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92: 1094–1100, [PUBMED], [INFOTRIEVE], [CSA]
- Zhao W., Parrish A. R., Ramos K. S. Constitutive and inducible expression of cytochrome P4501A1 and P4501B1 in human vascular endothelial and smooth muscle cells. In vitro Cell. Dev. Biol., Anim 1998; 34: 671–673, [CSA]
- Zhang Y., Ramos K. S. The induction of proliferative vascular smooth muscle cell phenotypes by benzo(a) pyrene does not involve mutational activation of ras genes. Mutat. Res. 1997; 373(2)285–292, [PUBMED], [INFOTRIEVE], [CSA]